Intercept Pharmaceuticals
3 known investors
Intercept Pharmaceuticals is a biopharmaceutical company developing medicines for rare and serious liver diseases, with research centered on Farnesoid X Receptor (FXR) biology for conditions such as severe alcohol-associated hepatitis. Founded in 2002, it is a wholly owned subsidiary of Alfasigma.
BiotechMedical Devices
Investors Β· 3
In the news
Frequently asked questions
- What does Intercept Pharmaceuticals do?
- Intercept Pharmaceuticals is a biopharmaceutical company developing medicines for rare and serious liver diseases, with research centered on Farnesoid X Receptor (FXR) biology for conditions such as severe alcohol-associated hepatitis. Founded in 2002, it is a wholly owned subsidiary of Alfasigma.
- Who are Intercept Pharmaceuticals's investors?
- Intercept Pharmaceuticals's investors include Aisling Capital, BioBrit, Ridgeback Capital.